Stockreport

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis [Yahoo! Finance]

89bio, Inc.  (ETNB) 
Last 89bio, inc. earnings: 3/18 04:05 pm Check Earnings Report
PDF —ENLIGHTEN-Cirrhosis, the second trial in the program, is planned to evaluate patients with compensated cirrhosis (F4) and is expected to initiate in the second quarter [Read more]